chevron_leftBack
As of 16 June 2026, Aprogen Biologics Inc. has a market cap of $32.67M USD, ranking #33672 globally and #2059 in South Korea.
It ranks #3043 in the Healthcare sector, and #1041 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$32.67MUSD
49.59B KRW
Enterprise Value
$195.36MUSD
296.56B KRW
Revenue (TTM)
$48.24MUSD
73.23B KRW
EBITDA (TTM)
-$68.32MUSD
-103.7B KRW
Net Income (TTM)
-$112.21MUSD
-170.33B KRW
EBITDA Margin
-142%
Profit Margin
-233%
PS Ratio
0.7
PB Ratio
0.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Jeong-Chool Kim
open_in_new
Employees
391
Founded
1960
Website
en.aprogen-pharm.com/index.do
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 5% | -93% | -94% | -97% | -97% | -98% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
003060
(주)에이프로젠바이오로직스
ISIN: KR7003060001
Shares Out.:
Shares Outstanding:
14.357M1
Shares Float:
6.214M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
2,565 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Aprogen Biologics Inc.
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 0126Z0
|
$9.16B
28K%
13.91T KRW
|
-
|
|
KRX: 000250
|
$6.79B
21K%
10.3T KRW
|
1958.1
|
|
KRX: 326030
|
$5.25B
16K%
7.97T KRW
|
29.9
|
|
KRX: 298380
|
$4.97B
15K%
7.55T KRW
|
-
|
|
KRX: 000100
|
$4.56B
14K%
6.92T KRW
|
35.9
|
|
KRX: 141080
|
$4.45B
14K%
6.76T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
2M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
2M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
1M%
|
97.4
|
|
SIX: RO
|
$320.51B
981K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.14B
882K%
215.59B GBP
|
27.6
|
|
NYSE: MRK
|
$274.03B
839K%
|
15.1
|
chevron_leftBack